NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-23-051 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.
Funding Opportunity PAR-23-052 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. For this announcement, unpublished preliminary data are limited to one figure, comprising no more than one-half page, to facilitate the entry of qualified new investigators to the field.
Funding Opportunity PAR-23-053 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R61/R33) mechanism to provide up to 2 years of R61 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Funding Opportunity PAR-23-054 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations.
Funding Opportunity PAR-23-025 from the NIH Guide for Grants and Contracts. Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-026 from the NIH Guide for Grants and Contracts. Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
Notice NOT-AR-23-004 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-010 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-019 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-047 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-23-002 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Heart, Lung and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), invites applications for the Central Biochemistry Laboratory (CBL) for the Chronic Kidney Disease in Children Study (CKiD) Consortium. The CBL will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and the Data Coordinating Center (DCC) of the study as a consortium.
Funding Opportunity RFA-DK-23-003 from the NIH Guide for Grants and Contracts. TheInterventions that Address Structural Racism to Reduce Kidney Health DisparitiesConsortium aims to foster community-engaged intervention research to address structural racism to reduce health disparities among individuals living with kidney disease. The Consortium will consist of one Research Coordinating Center and multiple Intervention Sites (seeRFA-DK-22-014)that will work collaboratively to develop, implement and evaluate meaningful interventions that aim to dismantle or mitigate the effects of structural racism to reduce kidney health disparities. This Funding Opportunity Announcement (FOA) invites applications for theResearch Coordinating Center(RCC) that will lead, manage, and harmonize efforts for the Consortium. The specific activities of the RCC will include: 1) providing organization, management, and administrative support of Consortium activities; 2) providing research coordination, data management and data analyses for Consortium studies; and 3) fostering research collaborations and helping to build a community of investigators with skills to develop, implement, and disseminate effective, scalable, and sustainable interventions that address the structural drivers of kidney health disparities.
Notice NOT-DK-23-001 from the NIH Guide for Grants and Contracts
Notice NOT-DK-23-002 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-22-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/).The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research.
Funding Opportunity PAR-24-022 from the NIH Guide for Grants and Contracts. This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.
Notice NOT-HG-23-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-002 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-23-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is one of three FOAs that will support a comprehensive effort by the National Cancer Institute (NCI) to provide infrastructure to develop and conduct national cancer screening clinical trials and studies through the Cancer Screening Research Network (CSRN). The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. This Network is designed to take advantage of large and diverse populations receiving routine care in a variety of healthcare settings. The CSRN will engage these populations in rigorous studies focused on cancer screening to improve early cancer detection and evaluate emerging cancer screening modalities with the ultimate goal of reducing cancer incidence, and cancer-related morbidity and mortality.